Following the announcement, Allergen shares immediately began to drop, most likely due to investor concern that the company will overpay to overtake Shire. In contrast, Shire share prices began to take off today. This comes as a result of increased investor confidence, facilitated by the mega-pharmaceutical fight for the company, and the hopes of a high buyout as a result. Takeda, in order to bounce back from this rejection, needs to find a means of acquiring a much greater capacity of wealth if it wishes to purchase Shire, which currently holds a higher market valuation, and compete with Allergan. Riding this wave of media spotlight has helped raise share prices 7.9% at peak trading on the day, and unlike Allergan and Takeda, Shire's earnings outlook in the short term is seemingly positive, regardless of this deal. Currently Shire holds a "B" grade for Growth, and a "B" grade for Value based in our Style Scores system.